Impact of intravenous dexmedetomidine on postoperative bowel movement recovery after laparoscopic nephrectomy: A consort-prospective, randomized, controlled trial

Table 1 Clinical characteristics of patients in groups C, D1, and D2

	Group C (n = 40)	Group D1 (n = 40)	Group D2 (n = 40)	P value
Sex, F/M	11/29	12/28	10/30	0.8820
Age, yr	52.73 ± 10.68	52.33 ± 7.99	51.73 ± 8.58	0.886
BMI, kg/m2	25.58 ± 2.70	26.15 ± 1.70	25.95 ± 2.04	0.505
Hypertension, Yes/No	11/29	12/28	15/25	0.606
DM, Yes/No	6/34	5/35	5/35	0.930
ASA, I/II	10/30	7/33	6/34	0.497
Duration of anaesthesia, min	148.95 ± 49.54	145.90 ± 47.24	144.60 ± 50.24	0.920
Duration of surgery, min	128.48 ± 46.83	130.90 ± 47.13	127.33 ± 50.18	0.944
Dosage of sufentanil during surgery, μg	32.58 ± 7.20	31.63 ± 3.28	32.75 ± 3.91	0.570
Dosage of sufentanil after surgery (8 h), mL	16.35 ± 0.51	16.15 ± 0.43	16.29 ± 0.53	0.180
Dosage of sufentanil after surgery (24 h), mL	48.41 ± 0.59	48.26 ± 0.76	48.30 ± 0.60	0.566
Postoperative stay in hospital, d	8.60 ± 1.72	8.38 ± 1.35	8.43 ± 1.68	0.803

Variables are presented as the mean ± SD or number of patients. None showed any statistical significance (P > 0.05). ASA: American Society of Anesthesiologists, BMI: Body mass index, DM: Diabetes mellitus.